Generic Medicine Info
Indications and Dosage
Muscle spasms
Adult: Initially, 25-50 mg daily, increased if required, to 150 mg or more daily.
Acute narrow-angle glaucoma, CNS depression or coma, myasthenia gravis, resp depression, coma, acute pulmonary insufficiency, sleep apnoea, severe hepatic impairment. Porphyria.
Special Precautions
Elderly or debilitated patients, pulmonary insufficiency, muscle weakness, organic brain changes, personality disorders, impaired liver or kidney function, history of alcohol or drug addiction due to risk of dependence. May precipitate suicide or aggressive behaviour.
Adverse Reactions
Drowsiness, sedation, muscle weakness, and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI upsets, changes in salivation, and amnesia. Rarely, jaundice, blood disorders, hypersensitivity reactions, raised liver enzyme values. Paradoxical excitation which may lead to hostility, aggression and disinhibition in some patients.
Impairment of consciousness, CNS depression, coma or paradoxical excitation. Symptomatic and supportive treatment. Activated charcoal may be given orally if within 1 hr of ingestion. Benzodiazepine antagonist, flumazenil, is rarely required and can be dangerous, especially in mixed overdoses involving TCA or in patients dependent on benzodiazepines.
Drug Interactions
Enhanced sedation or resp and CV depression may occur if given with other drugs that have CNS depressant properties, cisapride.
Potentially Fatal: Increased risk of severe hypotension and respiratory depression with clozapine.
Mechanism of Action: Tetrazepam is a benzodiazepine with general properties similar to those of diazepam. It is used for its muscle relaxant properties in the treatment of muscle spasm.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Tetrazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in